Literature DB >> 23133091

Varied presentations of gastrointestinal stromal tumour.

C V Kantharia1, R Irpatgire, R Y Prabhu, R D Bapat, A N Supe.   

Abstract

Gastrointestinal stromal tumours (GIST) are soft tissue tumours arising from the mesenchyma in the gastrointestinal tract. These are rare tumours. However, over the past few years with the better understanding of the pathogenesis of GIST and better imaging facilities, the diagnosis is made more frequently. The characteristic diagnostic feature of GIST is the expression of CD34 and receptor tyrosine kinase KIT, CD117 by these tumours. The use of tyrosine kinase inhibitor imatinib mesylate has led to improved outcome. The presentation of GIST however remains non-specific, and varies depending upon the size and the organ of origin. We present a series of four cases of GIST with varied presentation.

Entities:  

Keywords:  GIST; Imatinib; KIT; Mesenchymal tumours

Year:  2008        PMID: 23133091      PMCID: PMC3452352          DOI: 10.1007/s12262-008-0090-0

Source DB:  PubMed          Journal:  Indian J Surg        ISSN: 0973-9793            Impact factor:   0.656


  13 in total

Review 1.  A case for interstitial cells of Cajal as pacemakers and mediators of neurotransmission in the gastrointestinal tract.

Authors:  K M Sanders
Journal:  Gastroenterology       Date:  1996-08       Impact factor: 22.682

2.  Gastrointestinal stromal tumor workshop.

Authors:  J Berman; T J O'Leary
Journal:  Hum Pathol       Date:  2001-06       Impact factor: 3.466

3.  c-kit immunoreactive interstitial cells of Cajal in the human small and large intestine.

Authors:  P Rømert; H B Mikkelsen
Journal:  Histochem Cell Biol       Date:  1998-03       Impact factor: 4.304

Review 4.  Gastrointestinal stromal tumors: recent advances in understanding of their biology.

Authors:  M Miettinen; M Sarlomo-Rikala; J Lasota
Journal:  Hum Pathol       Date:  1999-10       Impact factor: 3.466

Review 5.  Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.

Authors:  G D Demetri
Journal:  Semin Oncol       Date:  2001-10       Impact factor: 4.929

Review 6.  Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis.

Authors:  M Miettinen; J Lasota
Journal:  Virchows Arch       Date:  2001-01       Impact factor: 4.064

7.  Cutaneous metastases from a gastrointestinal stromal tumor of the stomach: review of literature.

Authors:  Mohsen Shabahang; Alan S Livingstone
Journal:  Dig Surg       Date:  2002       Impact factor: 2.588

Review 8.  The role of adjuvant and neoadjuvant therapy in gastrointestinal stromal tumors.

Authors:  Margaret von Mehren
Journal:  Curr Opin Oncol       Date:  2008-07       Impact factor: 3.645

9.  Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.

Authors:  Burton L Eisenberg; Jonathan Harris; Charles D Blanke; George D Demetri; Michael C Heinrich; James C Watson; John P Hoffman; Scott Okuno; John M Kane; Margaret von Mehren
Journal:  J Surg Oncol       Date:  2009-01-01       Impact factor: 3.454

10.  CD34 expression by gastrointestinal tract stromal tumors.

Authors:  M van de Rijn; M R Hendrickson; R V Rouse
Journal:  Hum Pathol       Date:  1994-08       Impact factor: 3.466

View more
  2 in total

1.  Unusual presentation of gastrointestinal stromal tumor of stomach in neurofibromatosis type 1: a case report.

Authors:  Sudeepta K Swain; Robinson Smile; Tirou Arul; Dipak David
Journal:  Indian J Surg       Date:  2012-09-09       Impact factor: 0.656

2.  Gastric leiomyosarcoma as a rare cause of gastric outlet obstruction and perforation: a case report.

Authors:  Elroy P Weledji; George Enoworock; Marcelin Ngowe Ngowe
Journal:  BMC Res Notes       Date:  2014-07-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.